A Phase II trial of guadecitabine (G) plus atezolizumab (A) in patients with metastatic urothelial carcinoma (UC) progressing after initial checkpoint inhibitor therapy.

被引：0
|
作者：
Plimack, Elizabeth R. [1 ]
Campbell, Kerry [1 ]
Issa, Jean-Pierre J. [2 ]
Hahn, Noah M. [3 ]
Quinn, David I. [4 ]
Jang, Hyo Sik [5 ]
Hostetter, Galen [5 ]
Nichols, Peter W. [4 ]
Chung, Woonbok [2 ]
Madzo, Jozef [2 ]
Ohtani, Hitoshi [5 ]
Shen, Hui [5 ]
Hinoue, Toshinori [5 ]
Baylin, Stephen B. [3 ]
Jones, Peter A. [5 ]
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Coriell Inst Med Res, Camden, NJ USA
[3] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Van Andel Res Inst, Grand Rapids, MI USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT121
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Docetaxel plus vinorelbine in patients with metastatic breast cancer progressing after anthracycline therapy. Preliminary results
    Cuevas, JM
    Baena, JM
    Espinosa, E
    Centellas, M
    Dorta, J
    Janariz, J
    Vivanco, GL
    Madronal, C
    Baron, MG
    Milla, A
    ANNALS OF ONCOLOGY, 1998, 9 : 20 - 20
  • [22] A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)
    Dizman, Nazli
    Adra, Nabil
    Vaishampayan, Ulka N.
    Xiao, Lianchun
    Yuan, Ying
    Campbell, Matthew T.
    Gao, Jianjun
    Zurita, Amado J.
    Jonasch, Eric
    Tannir, Nizar M.
    Shah, Amishi Yogesh
    Msaouel, Pavlos
    Hahn, Andrew Warren
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Phase II trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer.
    Galsky, Matt D.
    Hahn, Noah M.
    Albany, Costantine
    Fleming, Mark T.
    Starodub, Alexander
    Twardowski, Przemyslaw
    Pal, Sumanta K.
    Hauke, Ralph J.
    Sonpavde, Guru
    Oh, William K.
    Bhardwaj, Nina
    Gnjatic, Sacha
    Kim-Schulze, Seunghee
    Liu, Ziyue
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [24] Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment
    Chan, Stephen L.
    Ryoo, Baek-Yeol
    Mo, Frankie
    Chan, Landon L.
    Cheon, Jaekyung
    Li, Leung
    Wong, Kwan H.
    Yim, Nicole
    Kim, Hyeyeong
    Yoo, Changhoon
    JOURNAL OF HEPATOLOGY, 2024, 81 (02) : 258 - 264
  • [25] Afatinib activity in platinum-refractory metastatic urothelial carcinoma (UC) patients with ErbB alterations: Results of a phase II trial.
    Choudhury, Noura
    Campanile, Alexa
    Antic, Tatjana
    Wade, James Lloyd
    Stadler, Walter Michael
    Nakamura, Yusuke
    O'Donnell, Peter H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [26] Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatinbased neoadjuvant chemotherapy.
    Koshkin, Vadim S.
    Natesan, Divya
    Zhang Li
    Oh, David Yoonsuk
    Porten, Sima P.
    Meng, Maxwell
    Pruthi, Raj
    Aggarwal, Rahul Raj
    Small, Eric Jay
    Fong, Lawrence
    Friedlander, Terence W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [27] MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
    He, Kai
    Berz, David
    Gadgeel, Shirish M.
    Iams, Wade T.
    Bruno, Debora S.
    Blakely, Collin M.
    Spira, Alexander I.
    Patel, Manish R.
    Waterhouse, David M.
    Richards, Donald A.
    Pham, Anthony
    Jotte, Robert
    Hong, David S.
    Garon, Edward B.
    Traynor, Anne
    Olson, Peter
    Latven, Lisa
    Yan, Xiaohong
    Shazer, Ronald
    Leal, Ticiana A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (07) : 907 - 921
  • [28] Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor
    Vogelzang, N. J.
    Hutson, T. E.
    Samlowski, W.
    Somer, B.
    Richey, S.
    Alemany, C.
    Loesch, D.
    Richards, P.
    Gardner, L.
    Sportelli, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients With Metastatic Urothelial Carcinoma
    Agarwal, Neeraj
    Apolo, Andrea B.
    Tsao, Che-Kai
    Lee, Karen M.
    Godbold, James H.
    Soto, Rothschild
    Poole, Austin
    Gimpel-Tetra, Kiev
    Lowe, Nancy
    Oh, William K.
    Galsky, Matthew D
    ONCOLOGIST, 2014, 19 (09): : 915 - 916
  • [30] Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
    Gebrael, Georges
    Jo, Yeonjung
    Thomas, Vinay Mathew
    Li, Haoran
    Sayegh, Nicolas
    Tripathi, Nishita
    Srivastava, Ayana
    Nordblad, Blake
    Dal, Emre
    Narang, Arshit
    Brundage, James
    Campbell, Patrick
    Fortuna, Gliceida Galarza
    Chehade, Chadi Hage
    Maughan, Benjamin L.
    Agarwal, Neeraj
    Swami, Umang
    CANCER, 2024, 130 (15) : 2621 - 2628
12345